This pioneering program, based at one of the world’s foremost academic medical centers within the Mass General Brigham healthcare system, represents a paradigm shift in managing kidney complications in oncologic settings. Previously, individuals suffering from complications such as acute kidney injury were managed under the general nephrology consult service, which lacked specialization in oncologic renal pathophysiology. The new onconephrology service specifically focuses on the dynamic renal manifestations of cancer and anticancer therapies, integrating state-of-the-art nephrology expertise with an in-depth understanding of oncology-related kidney insults.

The origin of this novel service is attributed in large part to Dr. Shruti Gupta, who also founded the American Society of Onconephrology (ASON) and acted as its inaugural president. Dr. Chowdhury currently serves as vice president. This society has grown to include members from fourteen countries worldwide, underscoring the global recognition of onconephrology as an indispensable field. At BWH, the team including co-first author Jessica Ortega meticulously documented their experience through a case study that was recently published in the Clinical Journal of the American Society of Nephrology.

The study provides invaluable insights into the establishment of the inpatient consult service, detailing its organizational framework, consultation pathways, and preliminary clinical outcomes observed in its inaugural year. The authors executed a comprehensive manual review contrasting data from July 2022 through June 2023—when oncology teams referred patients to the general nephrology service—with data between July 2023 and June 2024 after the onconephrology service’s inception. This comparison elucidated the tangible benefits of specialized nephrology care focused on cancer patients.

Notably, the findings revealed that patients with cancer-associated acute kidney injury managed by the onconephrology consult service demonstrated significantly higher rates of kidney recovery at hospital discharge compared to those treated by general nephrology. This suggests that domain-specific knowledge and tailored protocols implemented by onconephrologists can directly influence renal outcomes amid complex oncologic care. In contrast, the study observed no significant difference between groups concerning sodium level corrections, indicating the nuanced spectrum of renal-electrolyte disturbances in these patients.

The impact of the service extended beyond patient outcomes, as the research team conducted anonymous surveys of oncologists and advanced practice providers who frequently collaborate with nephrology specialists. An overwhelming majority—81%—found the dedicated onconephrology service beneficial, while 88% expressed strong inclination to utilize it again for future patients. This high degree of satisfaction highlights the critical role of specialized consultative services in multidisciplinary cancer care, facilitating seamless communication, and integrated treatment planning.

Importantly, the formation of the inpatient onconephrology team has also facilitated smoother transitions from hospital admission to outpatient follow-up, enabling longitudinal care that is attuned to the evolving renal needs of oncology patients. This continuum is essential because kidney complications often persist or emerge anew post-discharge, necessitating ongoing vigilance and management. The study thus sets a new benchmark for comprehensive onconephrology practices in inpatient and outpatient settings.

The methodologies applied in this case study were rigorous and clinically grounded. Manual chart reviews were performed to extract detailed patient data, focusing on parameters that reflect renal function recovery, electrolyte imbalances such as hyponatremia, and other key clinical endpoints pertinent to kidney disease in cancer. Such granularity in data collection ensures that observed differences in outcomes are attributable to the specialized nature of the consult service rather than confounding variables.

Looking forward, Drs. Chowdhury and Gupta emphasize the need for larger, multicenter studies employing more robust, prospective designs to evaluate causal effects and long-term outcomes comprehensively. Exploring the mechanisms by which onconephrology interventions improve kidney recovery will be critical in refining care protocols. Moreover, deepening collaborations between nephrologists and oncologists remains a top priority to proactively identify at-risk patients and tailor cancer therapies that minimize nephrotoxicity without compromising oncologic efficacy.

The inception of this inpatient onconephrology consult service is a leap toward personalized medicine in complex patients grappling with the dual burden of cancer and kidney disease. It underscores the importance of subspecialty integration and innovation in healthcare to confront multifaceted clinical challenges. While the promise of oncologic advances brings hope for longer survival, the accompanying risk of kidney complications demands vigilant, specialized management to preserve renal health and optimize overall patient outcomes.

This study, published online in April 2025 in the Clinical Journal of the American Society of Nephrology, not only provides a blueprint for institutions worldwide to replicate similar services but also fuels a nascent movement toward establishing onconephrology as a recognized subspecialty deserving of dedicated clinical and research focus. The Mass General Brigham system continues to lead the charge in merging academic excellence with compassionate, innovative care tailored to modern complexities in medicine.

Subject of Research: People

Article Title: Innovating Kidney Care in Patients with Cancer: The Development of an Inpatient Onconephrology Service

News Publication Date: 15-Apr-2025

Web References:
https://doi.org/10.2215/cjn.0000000714
https://www.massgeneralbrigham.org/en
https://www.ason-online.org/

References:
Chowdhury RB, Ortega JL, Wells SL, et al. Innovating Kidney Care in Patients with Cancer: The Development of an Inpatient Onconephrology Service. Clin J Am Soc Nephrol. Published online March 19, 2025. doi:10.2215/CJN.0000000714

Keywords: Kidney, Cancer patients

Tardigrades, often referred to as "water bears," are microscopic organisms that exhibit the extraordinary ability to withstand extreme environmental stressors, including high levels of radiation. These nearly indestructible beings can thrive in conditions that would be fatal to most life forms. This innate resilience has sparked the interest of scientists looking for novel ways to protect normal tissues from the deleterious effects of radiation during cancer therapy.

The pioneering team has developed a strategy that harnesses the unique properties of a protein produced by tardigrades, known as Dsup, which serves to safeguard DNA from radiation-induced damage. When the research team proceeded to inject messenger RNA skilled in encoding this protein into murine models, they observed a marked efficacy; the resulting Dsup protein successfully conferred a protective shield around the cellular DNA against the ravages of radiation exposure. If this strategy progresses to clinical application in humans, it could represent a transformative leap forward in treating cancer while minimizing collateral damage to healthy tissues.

Explaining the significance of their breakthrough, Giovanni Traverso, an associate professor at MIT and a gastroenterologist at Brigham and Women’s Hospital, emphasized the critical need to address the side effects associated with radiation therapy. Many patients face intolerable consequences such as inflammation in the mouth or rectum due to radiation, leading to difficulties in swallowing, eating, or, in severe cases, necessitating hospitalization. The dire need for protective strategies in cancer treatment is manifested in the discomfort and risks that accompany conventional radiation protocols.

The team led by Traverso and his colleague James Byrne has made significant strides toward formulating new solutions for mitigating the toxicities of radiation exposure. While a handful of drugs exist to attempt to reduce damage from radiation therapy, their effectiveness is limited. Furthermore, current protective measures, such as hydrogels for prostate cancer radiation treatments, do not address the broader spectrum of complications experienced by many cancer patients receiving radiation.

Inspired by tardigrades and their survival mechanisms, the research team focused on Dsup protein’s role in defending DNA from radiation. This protein allows tardigrades to survive radiation levels thousands of times higher than those lethal to humans. The researchers proposed using mRNA encoding for Dsup to instruct human cells to produce the protective protein before administering radiation therapy. This approach posits a transient expression that acts directly at the cellular level to enhance resilience whilst limiting potential long-term risks associated with genetic manipulation.

For successful implementation, the research necessitated the development of an effective delivery mechanism for the mRNA. After rigorous experimentation, the researchers identified polymer-lipid nanoparticles that efficiently transported mRNA to target tissues. By optimizing these delivery systems, they combined the properties of various materials, achieving both the potency required for the delivery of the mRNA and the specificity needed to avoid unintended effects.

In preclinical trials conducted on mice, the research team demonstrated the potential of their approach. By administering nanoparticle-encapsulated mRNA near the targeted areas before radiation exposure, they successfully reduced the occurrence of double-stranded DNA breaks—effectively cutting the damage inflicted by radiation in half. Importantly, they noted that the protective effects were localized, ensuring that tumor tissues remained vulnerable to radiation while safeguarding adjacent healthy cells.

Moving forward, the remarkable findings provoke further questions regarding the translation of this therapeutic paradigm into human applications. The core challenge lies in developing a variant of the Dsup protein that does not incite an immune response, as the introduction of foreign proteins could lead to unintended inflammatory reactions in human patients. If this obstacle can be successfully navigated, the implications for cancer treatment could be profound—offering not just protection from radiation but potentially safeguarding healthy tissues from the side effects of chemotherapy drugs.

Beyond oncology, there is a promising horizon for this research. Consideration is being given to the potential application of Dsup-derived therapies in protecting astronauts from radiation exposure during prolonged space missions, an area that is increasingly relevant as space travel becomes more commonplace. The global interplay between cancer treatment, space exploration, and biomedical innovation leaves an exciting landscape for future discoveries.

This groundbreaking work, which recently made its debut in the prestigious journal Nature Biomedical Engineering, encapsulates a modern approach to an age-old challenge in medicine. The confluence of marine biology and cancer research exemplifies the innovative thinking emerging from interdisciplinary collaboration. As researchers continue to explore the depths of nature for solutions to human health challenges, the hope remains that strategies exemplified by the humble tardigrade may help change the trajectory of cancer care.

The ongoing studies underscore the value of basic research in uncovering novel therapeutic avenues and showcase the extraordinary capabilities of biological systems in extreme conditions. The next steps involve extensive preclinical and clinical trials to verify safety and efficacy before mRNA therapies become part of standard cancer care. As science continues to unravel the secrets hidden within the natural world, the potential for revolutionary breakthroughs in medicine continues to grow, steadily illuminating paths toward enhanced patient care and novel treatment strategies.

Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:

Keywords: